Indoco Remedies' Q1 FY 2025-26 Quarterly Results

Result Summary

• Indoco Remedies Ltd reported a 2.8% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Jun (Q1 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 1.6%.
• Its expenses for the quarter were up by 8.5% QoQ and 11.9% YoY.
• The net profit decreased 265.0% QoQ and decreased 2097.3% YoY.
• The earnings per share (EPS) of Indoco Remedies Ltd declined at 3.9 during Q1 FY 2025-26.

Financial Statments for Q1 FY 2025-26

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Indoco Remedies Ltd is a pharmaceutical company based in India, primarily engaged in the manufacture and sale of pharmaceutical formulations and active pharmaceutical ingredients (APIs). The company operates in the healthcare sector and offers a wide range of products, including prescription drugs, over-the-counter (OTC) products, and APIs, catering to both domestic and international markets. Indoco Remedies has a significant presence in several therapeutic segments such as anti-infectives, anti-diabetics, and gastroenterology, among others. The company is known for its focus on quality and innovation in drug development. As of my last update, no major recent developments were identified for Indoco Remedies Ltd beyond this scope.

Revenue

For the first quarter of the fiscal year 2026 (Q1FY26), Indoco Remedies Ltd reported total income of ₹439.52 crores. This represents a slight year-over-year (YoY) increase of 1.6% compared to ₹432.52 crores in the first quarter of fiscal year 2025 (Q1FY25). However, there was a quarter-over-quarter (QoQ) decline of 2.8% from ₹452.30 crores in the fourth quarter of fiscal year 2025 (Q4FY25). The data suggests a moderate growth in total income on an annual basis, with a decrease when compared to the previous quarter.

Profitability

In Q1FY26, the company experienced a loss with a Profit After Tax (PAT) of -₹36.35 crores, a significant decrease from the profit of ₹22.03 crores reported in Q4FY25, marking a QoQ change of -265.0%. Compared to Q1FY25, where the PAT was ₹1.82 crores, the YoY change was -2097.3%. The Earnings Per Share (EPS) for Q1FY26 stood at -₹3.90, down from ₹2.40 in the previous quarter and ₹0.20 in the same quarter last year, reflecting a similar trend in QoQ and YoY percentages. The negative PAT and EPS figures indicate challenges in maintaining profitability within the current period.

Operating Metrics

The total expenses for Indoco Remedies in Q1FY26 amounted to ₹476.18 crores, marking an 11.9% increase YoY from ₹425.55 crores in Q1FY25, and an 8.5% increase QoQ from ₹439.05 crores in Q4FY25. The Profit Before Tax (PBT) was recorded at -₹36.66 crores in Q1FY26, showcasing a substantial QoQ decline from ₹32.98 crores in Q4FY25 and a YoY decline from ₹6.97 crores in Q1FY25. The tax expenditure for Q1FY26 was minimal at -₹0.31 crores, compared to ₹10.95 crores in Q4FY25 and ₹5.15 crores in Q1FY25, showing negative growth both QoQ and YoY. The operating metrics indicate a rise in expenses, which has impacted the profitability and tax components negatively for the quarter.